Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

armeeapotheke - death adder antivenom

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

armeeapotheke - immunoglobulinum monovalentum equis antarcticus d'antarcticus - death adder antidote - lösung: immunoglobulinum monovalentum equis acanthophis antarcticus 6000 u.i. natrii chloridum, conserv.: phenolum ≤ 0.22 % m/v, aqua ad iniectabile q.s. ad solutionem. - antivenin - antivenine

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - carcinome, poumon non à petites cellules - antinéoplasiques et agents immunomodulateurs, des anticorps monoclonaux - nivolumab bms est indiqué pour le traitement du cancer du poumon non à petites cellules squameux localement avancé ou métastatique (nsclc) après une chimiothérapie chez l'adulte.

Union européenne - français - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agents antinéoplasiques - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq en monothérapie est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique nsclc après une chimiothérapie antérieure. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Canada - français - Health Canada

norbrook laboratories ltd. - tulathromycine - solution - 100mg - tulathromycine 100mg - bétails; porcs; mouton

Canada - français - Health Canada

alivira animal health limited - tulathromycine - solution - 100mg - tulathromycine 100mg - bétails; bétails; bétails; bétails; porcs; mouton

Canada - français - Health Canada

elanco canada limited - tilmicosin - solution - 300mg - tilmicosin 300mg - bétails; mouton

Canada - français - Health Canada

auro pharma inc - candésartan cilexétil; hydrochlorothiazide - comprimé - 16mg; 12.5mg - candésartan cilexétil 16mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists